ARVN vs. GERN, DYN, RYTM, RNA, MRVI, PTCT, INDV, VERA, ARDX, and CORT
Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Geron (GERN), Dyne Therapeutics (DYN), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Maravai LifeSciences (MRVI), PTC Therapeutics (PTCT), Indivior (INDV), Vera Therapeutics (VERA), Ardelyx (ARDX), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceutical preparations" industry.
Geron (NASDAQ:GERN) and Arvinas (NASDAQ:ARVN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Geron received 308 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 69.52% of users gave Geron an outperform vote while only 65.27% of users gave Arvinas an outperform vote.
Geron currently has a consensus target price of $6.10, suggesting a potential upside of 56.41%. Arvinas has a consensus target price of $61.13, suggesting a potential upside of 89.09%. Given Geron's stronger consensus rating and higher probable upside, analysts plainly believe Arvinas is more favorable than Geron.
Arvinas has a net margin of -185.09% compared to Arvinas' net margin of -38,730.00%. Geron's return on equity of -64.79% beat Arvinas' return on equity.
73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 3.0% of Geron shares are owned by company insiders. Comparatively, 5.2% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Arvinas had 31 more articles in the media than Geron. MarketBeat recorded 34 mentions for Arvinas and 3 mentions for Geron. Arvinas' average media sentiment score of 0.85 beat Geron's score of 0.15 indicating that Geron is being referred to more favorably in the media.
Geron has higher earnings, but lower revenue than Arvinas. Geron is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Geron has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.
Summary
Arvinas beats Geron on 12 of the 18 factors compared between the two stocks.
Get Arvinas News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
